Switching to Biphasic Insulin Aspart 30 in Patients Uncontrolled on Human Premix Insulin

2010 ◽  
Vol 7 (2) ◽  
pp. 124
Author(s):  
Jens Sandahl Christiansen ◽  
Keyword(s):  
Insulin Aspart ◽  
Postprandial Glucose ◽  
Nocturnal Hypoglycaemia ◽  
Glucose Lowering ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30 ◽  
Neutral Protamine Hagedorn ◽  
Glucose Lowering Effect

Two cases relating to switching from biphasic human insulin 30 (BHI 30) to biphasic insulin aspart 30 (BIAsp 30) are described. Case 1: switching from BHI 30 to BIAsp 30 due to inadequate glycosylated haemoglobin (HbA1c) control. Case 2: switching from BHI to BIAsp 30 due to nocturnal hypoglycaemia. Case 1: HbA1cfell from 7.9 % with BHI to 6.9 % with BIAsp 30 at the six-month follow-up. Postprandial glucose (PPG) fell from 12.6 mmol/l with BHI to 9.1 mmol/l with BIAsp 30. Case 2: a man who had experienced recurrent nocturnal hypoglycaemia with neutral protamine Hagedorn (NPH) or BHI was able to maintain his glycaemic control without severe nocturnal hypoglycaemia with BIAsp 30. BIAsp 30 offers advantages over BHI 30 in terms of faster absorption, higher peak concentrations, and a more rapid and pronounced prandial glucose-lowering effect, which means that BIAsp 30 can improve PPG control and reduce the risk of nocturnal and major hypoglycaemic episodes.

Biphasic Insulin Aspart 30 in Insulin Initiation

2010 ◽  
Vol 7 (2) ◽  
pp. 121
Author(s):  
Wenying Yang ◽  
Keyword(s):  
Blood Glucose ◽  
Glycaemic Control ◽  
Insulin Aspart ◽  
Fasting Blood Glucose ◽  
Postprandial Glucose ◽  
Insulin Initiation ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30 ◽  
Clinical Literature

This case report concerns a patient with poor glycaemic control on oral antidiabetic drugs who initiated biphasic insulin aspart 30 (BIAsp 30), and reviews supporting clinical literature, alternative treatment choices and the options for intensification. During the six-month follow-up after initiation of BIAsp 30, glycosylated haemoglobin (HbA1c) was reduced from 10.2 % to 6.4 %, mean fasting blood glucose (FBG) was reduced from 9.0 mmol/l to 6.8 mmol/l and mean postprandial glucose (PPG) was reduced from 15.3 mmol/l to 8.8 mmol/l. Body weight increased by 4 kg. The patient experienced eight episodes of hypoglycaemia over the six-month period (four pre-lunch, one at bedtime and three nocturnal). The patient had six episodes with blood glucose (BG) <4.0 mmol/l but no episodes with BG <2.8 mmol/l. Insulin initiation with a premix insulin analogue offers a simple and convenient regimen of once- or twice-daily dosing and provides effective glycaemic control by providing coverage of both FBG and PPG.

scholarly journals Initiation of Biphasic Insulin Aspart in a Patient Failing Basal Insulin Treatment

2010 ◽  
Vol 7 (2) ◽  
pp. 127
Author(s):  
Janusz Gumprecht ◽  
Keyword(s):  
Insulin Glargine ◽  
Insulin Aspart ◽  
Postprandial Glucose ◽  
Dose Titration ◽  
Insulin Intensification ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30 ◽  
Clinical Literature ◽  
History Of

This case illustrates insulin intensification from insulin glargine to biphasic insulin aspart 30 (BIAsp 30), reviews supporting clinical literature and discusses alternative therapeutic approaches. PL, a 56-year-old male with an eight-year history of type 2 diabetes, needed to intensify his insulin glargine treatment as he was not achieving appropriate blood glucose targets and recurrent hypoglycaemia limited further dose titration. With insulin glargine, his glycosylated haemoglobin (HbA1c) was 7.8 %, his fasting plasma glucose (FPG) ranged from 7.2 mmol/l to 8.0 mmol/l and his postprandial glucose (PPG) ranged from 8.9 mmol/l to 10.6 mmol/l, being especially high after dinner. At four months after the switch to BIAsp 30, his HbA1cwas 6.9 % and his FPG and PPG levels were at goal. The patient had not experienced any hypoglycaemic episodes. By addressing both PPG and FPG, intensification with BIAsp 30 provided improved glycaemic control without the hypoglycaemia experienced with insulin glargine.

scholarly journals Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis

2013 ◽  
Vol 4 (2) ◽  
pp. 347-361 ◽  
Author(s):  
Mohammad Ebrahim Khamseh ◽  
Jihad Haddad ◽  
Wenying Yang ◽  
Alexey Zilov ◽  
Ole Molskov Bech ◽  
...  
Keyword(s):  
Insulin Aspart ◽  
Age Groups ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30

scholarly journals Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

Diabetes Care ◽  
2014 ◽  
Vol 37 (8) ◽  
pp. 2084-2090 ◽  
Author(s):  
Gregory R. Fulcher ◽  
Jens Sandahl Christiansen ◽  
Ganapathi Bantwal ◽  
Miroslawa Polaszewska-Muszynska ◽  
Henriette Mersebach ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Insulin Degludec ◽  
Treat To Target ◽  
Target Trial ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30
Sign in / Sign up

Export Citation Format

Share Document